Y-mAbs Therapeutics announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging, SNMMI, 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Canada. The poster titled “High-affinity and specific binding between DOTA-chelated lanthanides and GD2-SADA, a self-assembling and disassembling bispecific fusion protein for pre-targeted” (poster #241436) characterizes the binding properties of GD2-SADA, a Self-Assembling and DisAssembling bispecific fusion protein used in a two-step approach to pre-targeted radioimmunotherapy. Building on previous studies, the analysis demonstrates real-time, high-affinity binding interactions between the GD2-SADA protein and several “caged” lanthanide metals with diagnostic and therapeutic applications.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
- Y-mAbs Therapeutics appoints LaFrance as Chief Development Officer
- Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
- Y-mAbs Therapeutics announces publication of preclinical GD2-SADA data at ASCO
- Y-mAbs Therapeutics announces interim analysis of Phase 2 data for Naxitamab